Tyloxapol
 |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | R05CA01 (WHO) |
| Identifiers | |
|
|
| CAS Number | 25301-02-4  |
| PubChem (CID) | 71388 |
| DrugBank | DB06439  |
| ChemSpider | None |
| UNII | Y27PUL9H56 |
| KEGG | D03261 |
| ChEMBL | CHEMBL1201548 |
| ECHA InfoCard | 100.209.660 |
| Chemical and physical data | |
| Formula | (C15H21O(C2H4O)m)n |
| Molar mass | variable |
| (what is this?) (verify) |
|
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.
With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]
Tyloxapol is the main active ingredient of the medical device Tacholiquin®. Tacholiquin® is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are Exosurf and Alevaire.
References[edit]
- ^ Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653
. PMID 8151722. - ^ Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.
- ^ Drugs.com: Tyloxapol definition
- ^ Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology. 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.
 |
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
